Biofrontera Inc
NASDAQ:BFRI 12:40:05 AM EDT
Market Cap (Intraday) | 11.71M |
Current PE | N/A |
Forward PE | N/A |
2yr Forward PE | N/A |
10-Day MA | $8.54 |
50-Day MA | $9.85 |
200-Day MA | $12.66 |
Biofrontera Inc Stock, NASDAQ:BFRI
120 Presidnetial Way, Suite 330, Woburn, Massachusetts 01801
United States of America
Phone: +1.781.245.1325
Number of Employees: 81
Description
Biofrontera, Inc. is a biopharmaceutical company, which engages in the commercialization of pharmaceutical products. It specializes in the treatment of dermatological conditions, caused primarily by exposure to sunlight that results in sun damage to the skin. The company is focused on the treatment of actinic keratosis and markets a topical antibiotic for treatment of impetigo. Its products include Ameluz and Xepi, its two prescription drugs, and BF-RhodoLED, a lamp used with Ameluz, for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company was founded on March 3, 2015 and is headquartered in Woburn, MA.